Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seniors Should Understand "Consequences" Of Leaving Medicare Rx, Governors Say

This article was originally published in The Pink Sheet Daily

Executive Summary

"If an individual doesn't like their prescription drug plan, opts out of it…Medicaid is not going to be there," NGA's Matthew Salo says. States will likely have to establish a safety net for dual eligibles who opt out of Medicare.

You may also be interested in...



Medicaid Cost-Containment Strategies May Include PDL For Antipsychotics

Increased flexibility in controlling drug costs will be required for states to maintain their bargaining power following the shift of “dual eligibles” to Medicare in 2006, Oklahoma Medicaid director says.

Medicare Rx Benefit Is "Net Negative" Among Seniors, Republican Pollster Says

A clear explanation of the law has not been communicated, Bill McInturff says. AARP will begin airing a commercial by the end of the month to help explain the Medicare Rx benefit.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059306

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel